Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: A single-center Phase I study.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2012
At a glance
- Drugs Pasireotide (Primary)
- Indications Cancer; Neuroendocrine tumours
- Focus Pharmacokinetics
- 01 Aug 2012 New trial record